drugset / Trial / NCT02822742

A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study

NCT02822742

Phase 3 Completed 26 enrolled Santen Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purposes of this study are to investigate the effect of intraocular pressure lowering efficacy and safety of DE-117 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension who are non-/low-responders to latanoprost ophthalmic solution.

Timeline

Start
2016-07-02
Primary completion
2017-04-28
Completion
2017-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject omidenepag isopropyl Small molecule 0.002 % Other
Background Latanoprost Small molecule 0.005 % Other

Indications